Search
Chemomab Therapeutics Ltd
CMMBAdd to Watchlist
2.270USD
+0.550+31.98%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
65.38MMarket Cap
13.03P/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
2
analysts
Strong Buy
Current Rating
15.000
Target Price
+782.35%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Chemomab Therapeutics Ltd
CMMB
2
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Chemomab Therapeutics Ltd's price target?
Analysts forecast that Chemomab Therapeutics Ltd's price target is USD 26.50, with the highest forecast at USD 28.00 and the lowest forecast at USD 25.00.
How have Chemomab Therapeutics LtdCMMB's recent earnings per share performed?
The market expectation was USD -0.22, while Chemomab Therapeutics LtdCMMB's earnings per share (EPS) for the previous quarter was USD -0.24. EPS for the next quarter is expected at USD -0.15.
What is the analyst rating for Chemomab Therapeutics Ltd?
Based on the ratings of Chemomab Therapeutics Ltd's stock from 2 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.